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Over the past 5 years or so, developmental geneticists 
studying the nematode and the fruit fly have provided 
many new insights into the signaling pathways linking cell 
surface receptor tyrosine kinases with nuclear transcrip- 
tion factors. A central component in this information trans- 
fer mechanism is the RAS protein, a low molecular weight 
GTP-binding protein that is a proto-oncogene product in 
mammals; another key player is the RAF kinase, also a 
proto-oncogene product in mammals, which is directly reg- 
ulated by RAS and in turn controls the mitogen-activated 
protein (MAP) kinase cascade. The workings of this sys- 
tem have been elucidated largely through a combination 
of biochemical studies in mammalian cells and genetic 
analysis of the formation of the vulva in Caenorhabditis 
elegans and photoreceptor cells in the Drosophila eye. 
Until now, the biochemical and genetic approaches have 
moved forward fairly much together, such that some shau- 
vinistic biochemists have been able to claim that they have 
never learned much new from flies or worms. But all that 
has now been changed by three reports in this issue of 
Ce//(Therrien et al., 1995; Sundaram and Han, 1995; Korn- 
feld et al., 1995) characterizing a novel member of this 
system, KSR-1, that has not been glimpsed in mammals. 
The components of the RAS signaling pathways defined 
in flies and worms are shown in Figure 1, along with their 
mammalian homologs. In C. elegans, loss of function of 
RAS or other components results in a failure of the vulva to 
form in hermaphrodite worms (the vulvaless phenotype), 
while gain of function leads to formation of excess vulvas 
(the multivulva phenotype). These effects are due to 
changes in the developmental pathway chosen by multipo- 
tent vulva1 precursor cells. Of course, the function of RAS 
is not limited to determining the development of the vulva: 
a number of other pathways are affected, but this one is 
just the most sensitive to minor perturbations (Sternberg, 
1993). In Drosophila, RAS function has been studied in 
detail in two signaling systems, Sevenless and Torso. In 
the developing eye, defects in RAS function result in failure 
of precursor cells to form the photoreceptor cell R7, while 
activation of RAS leads to nonneuronal cone cells devel- 
oping into extra R7 cells, resulting in a characteristic 
roughened appearance of the eye. Torso triggers a signal 
transduction cascade involved in the development of ante- 
rior and posterior extremities: loss of function in this path- 
way leads to a failure of these extremities to develop (Perri- 
mon, 1994). 
Homologs of all the various components of these signal- 
ing pathways have been identified in mammals. In the 
mammalian system, there is considerable biochemical ev- 
idence for branching, feedback, and cross-talk in the RAS 
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pathway, which at first may seem at odds with the appar- 
ently linear pathways defined in C. elegans and Drosoph- 
ila. However, as will be discussed below, there are also 
increasing genetic data that these pathways are not as 
straightforward as they at first seemed. 
In C. elegans, Sundaram and Han (1995) and Kornfeld 
et al. (1995) have identified a novel suppressor of the acti- 
vated RAS-induced multivulva phenotype. The sequence 
of this gene shows that it encodes a kinase that is fairly 
distantly related to C. elegans RAF/LIN-45 (31% identity 
in the kinase domain) and mammalian RAF (35% identity), 
the best-characterized direct effector of RAS. The gene 
was therefore named ksr-7, for kinase suppressor of RAS. 
The genetic epistasis analysis shows that KSR-1 acts 
downstream or parallel to RAS and upstream of a putative 
transcription factor, LIN-1 (Kornfeld et al., 1995). Defects 
in KSR-1 function synergize with defects in RAFILIN-45 
and SUR-l/MPK-1 (a MAP kinase homolog) to give a more 
severe vulvaless phenotype. In the worm it has not been 
determined where KSR-1 acts relative to RAF. 
There are a number of unexpected and provocative ob- 
servations about KSR-1 in C. elegans. One is that the 
loss-of-function ksr-7 alleles that block the induction of 
multiple vulvas by activated RAS (let-60@7046gf), a G13E 
point mutation known to be transforming in mammals) 
have no effect on the vulva1 development pathway in other- 
wise wild-type animals. Also, loss of function of KSR-1 has 
a much greater effect on the multivulva phenotype induced 
by overexpression of activated RAS than that induced by 
overexpression of wild-type RAS. In addition, defects in 
KSR-1 have no effect on multivulva formation due to loss 
of LIN-15, an upstream negative regulator of the pathway. 
All of this points to KSR-1 function being more critical for 
the effects of mutationally activated RAS than the effects 
of wild-type RAS. This is somewhat counterintuitive: acti- 
vated mutant RAS is normally thought to provide a 
stronger and more prolonged signal than wild-type RAS, 
and it would therefore be expected to be harder to disrupt 
signaling from mutant as opposed to wild-type RAS. A 
possible explanation might be that RAS interacts directly 
with KSR-1 and that the GlSE-activated mutant of RAS 
has a significantly lower affinity for KSR-1 than does wild 
type. Weaker than wild-type binding of activated RAS mu- 
tants to RAF has been reported (Herrmann et al., 1995). 
Alternatively, again assuming direct RAS-KSR-1 interac- 
tion, the inactive KSR-1 mutant proteins could have domi- 
nant negative effects. Since they have all suffered point 
mutations, mostly in the kinase domain, these proteins 
could still interact with RAS and block its interaction with 
other effecters such as RAF. Forwild-type RAS, this nega- 
tive effect would be compensated partially by protecting 
RAS from inactivation by GTPase-activating proteins that 
interact at the same effector site; activated RAS mutants 
are already GAP insensitive and so would be more suscep- 
tibletodominant negativeeffects(Farnsworthetal., 1991). 
In Drosophila, Therrien et al. (1995) have found two 
suppressors of the G12V-activated mutant RAS-induced 
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Figure 1. Established RAS Signaling Pathways in Drosophila and C. 
elegans and Their Homologs in Mammalian Cells 
Components of the worm vulva1 development pathway and the fly 
photoreceptor development pathway (Sevenless) are shown. Arrow- 
heads represent stimulatory interactions while bars represent inhibi- 
tory interactions. Abbreviations: MAPK, MAP kinase; MAPKK, MAP 
kinase kinase; MAPKKK, MAPKK kinase; See text for details. 
rough eye phenotype. One suppressor encodes a protein 
with homology to the 6 subunit of geranylgeranyl trans- 
ferase: defects in this enzyme probably block RAS iso- 
prenylation in Drosophila, thereby leading to RAS inactiva- 
tion due to failure to localize to the membrane correctly. 
Unlike in mammals where RAS is farnesylated, Drosophila 
RAS is geranylgeranylated. The other suppressor appears 
to be the fly homolog of KSR-1, sharing 41% identity in 
the kinase domain to the worm KSR-1 protein. (Bycompar- 
ison, the relationship between fly and worm RAF is 63% 
identity in the kinase domain.) While KSR-1 defects sup- 
press the effects of activated RAS, they do not suppress 
the rough eye phenotype due to activated RAF: thus, 
KSR-1 acts downstream of or on a parallel pathway to 
RAS, but upstream of or possibly on a parallel pathway 
to RAF. In addition to acting in the Sevenless pathway, 
ksr-7 loss-of-function mutations also result in defects in 
theTorso pathway. There are, however, a number of differ- 
ences between KSR-1 function in flies and in worms. One 
of the most striking is that loss-of-function mutations in 
ksr-7 are recessive lethal in flies, but only have a larval 
lethal effect in a small percentage of worms. This could 
suggest either a redundancy in the signaling pathways 
involving KSR-1 in worms that is lacking in flies or perhaps 
significant divergence of function of KSR-1 between the 
two organisms. 
In addition to cloning Drosophila melanogaster KSR-1, 
Therrien et al. (1995) have also cloned homologs in Dro- 
sophila virilis, mouse, and human. In each species, the 
kinase domain shows more similarity to RAF than to any 
other previously described kinase. However, there are a 
number of unusual structural features in the sequence of 
KSR-1 that make it hard to predict whether it will have 
serinelthreonine kinase activity, like RAF, or tyrosine ki- 
nase activity. Lack of homology in kinase subdomain VIII 
also suggests that KSR-1 may have different substrates 
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Figure 2. Two Possible Speculative Models for KS&l Function in the 
RAS Pathway 
Established pathways are shown in black, while hypothetical interac- 
tions are in red. Single black arrows between two proteins indicate 
a proven direct interaction. Proteins whose existence has not been 
established are written in red. Abbreviations: MAPK, MAP kinase; 
MEK, MAPK/ERK kinase; DAG, diacylglycerol; PLCy, phospholipase 
Cy; PKC, protein kinase C. See text for details. 
(A) KSR-1 as an additional effector of RAS. Owing to its similarity to 
RAF, KSR-1 could be controlling a pathway related to MAP kinase. 
Both this pathway and the MAP kinase pathway would be required 
for downstream RAS effects. Activation of downstream components 
of this pathway by aberrantly strong activation of RAF could explain 
the inability of KSR-1 mutants to block oncogenic mutant RAF effects 
(broken red arrow). 
(B) KSR-1 as a coactivator of RAF. KSR-1 could be responsible for 
phosphorylating and activating RAF presented to it by RAS-GTP at 
the plasma membrane. Loss of KSR-1 would result in an inability to 
activate RAF, but would be overcome by constitutive activation of RAF. 
KSR-1 might beactivated indirectly by receptortyrosine kinases, possi- 
bly acting through phospholipase Cy and protein kinase C or through 
direct diglyceride binding to the zinc finger of KSR-1. 
from RAF. Like RAF, KSR-1 has a cysteine-rich zinc finger 
clearly related to those in protein kinase C that bind phor- 
bol esters and diglycerides. However, KSR-1 lacks the 
serinelthreonine-rich CR2 motif shared by RAF family pro- 
teins. Perhaps more significantly, KSR-1 does not show 
similarity to the RAS-binding site of RAF, immediately 
amino-terminal to the zinc finger, and therefore may not 
share RAF’s ability to interact directly with RAS. Attempts 
to show interaction of RAS and KSR-1 in the yeast two- 
hybrid system have not been successful. 
What models can be suggested for the action of KSR-1 
in the RAS signaling pathway? From both flies and worms, 
it is clear that KSR-1 must function either downstream of 
RAS or on a parallel pathway that is required for the cell 
to respond correctly to activation of the RAS pathway. If 
KSR-1 functions downstream of RAS (see Figure 2) it may 
interact with it directly. Since RAS is well documented to 
interact directly with RAF, it is highly unlikely that KSR-1 
could be linking RAS to RAF in a linear sequence. How- 
ever, KSR-1 could be another effector of RAS. Many direct 
effecters of RAS other than RAF are now known: adenylyl 
cyclase in budding yeast; ByR, a MAP kinase kinase ki- 
nase unrelated to RAF, and Scdl, an exchange factor 
for the Rho family protein Cdc42, in fission yeast; and 
phosphoinositide 3-OH kinase, Ral-GDS, and possibly 
GAPS and other proteins in mammals (see Rodriguez- 
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Viciana et al., 1994, and references therein; White et al., 
1995, and references therein). All these proteins have 
RAS-binding sites that are unrelated to RAF in primary 
sequence, and several do not score positive in yeast two- 
hybrid screens. Indeed, there are some indications that 
the RAF zinc finger by itself, which is shared by KSR-1, 
may be able to bind to RAS (Brtva et al., 1995). A very 
simple model is that RAS activates KSR-1 directly that in 
turn switches on a signaling pathway acting in parallel to 
the RAF/MAP kinase pathway (Figure 2A). Owing to the 
similarity of KSR-1 to RAF, this pathway might perhaps 
be another kinase cascade of MEK and ERK-related ki- 
nases. At some point downstream, both this pathway and 
the MAP kinase pathway would be required for biological 
effects associated with an activated RAS phenotype. A 
major weakness of this model is that it does not readily 
explain why activated RAF can bypass the loss of function 
of KSR-1, while both pathways are required for RAS func- 
tion. A possible explanation of this could be that activated 
RAF mutants generate superphysiological levels of signal 
that could lead to activation of a parallel pathway down- 
stream of KSR-1, particularly if it was made up of compo- 
nents related to those of the MAP kinase pathway. Such 
crossover between the MAP kinase and the related stress- 
activated protein kinase pathways has been found when 
mammalian MEK kinase is overexpressed (Yan et al., 
1994). 
An alternative model for KSR-1 function is that it acts 
parallel to RAS as an upstream activator of RAF. If both 
RAS and KSR-1 input was required to activate RAF, this 
would explain why in flies KSR-1 defects blocked RAS 
signaling but had no effect on RAF signaling. In Drosoph- 
ila, a RAS-independent activation of RAF has been postu- 
lated in the Torso pathway, where defects in RAF have 
more severe effects than disruption of RAS (Hou et al., 
1995). While this might be explicable by some other RAS- 
related proteins such as RAS2 or RAS3 (fly equivalents 
of R-RAS and RAP) or as-yet-unidentified RAS homologs 
carrying some of the signal, the model in Figure 2B is 
perhaps more plausible. From biochemical analysis of 
RAF function in mammalian cells, it is known that while 
interaction of RAF with RAS contributes to RAF activation, 
it is not sufficient. The current consensus is that binding 
of RAF to membrane bound RasGTP causes the kinase 
to translocate to the plasma membrane where it receives 
a second activation signal (or signals) that renders it no 
longer dependent on RAS. The nature of this second sig- 
nal is unclear but appears very likely to involve phosphory- 
lation of RAF. A physiologically significant regulatory role 
for the interaction of RAF with 14-3-3 proteins appears to 
be less likely. Dent et al. (1995a) have shown that human 
RAF1 can be inactivated by either serinelthreonine or tyro- 
sine phosphatase treatment, while Marais et al. (1995) 
have shown that tyrosine phosphorylation of human RAF1 
by Src can provide this second activation signal, in 
agreement with previous work showing that mutation of 
RAF1 tyrosine residues 340 or 341 to acidic residues acti- 
vates the kinase (Fabian et al., 1993). However, it should 
be noted that the equivalent residues in Drosophila and 
C. elegans RAF and also in mammalian A- and B-RAF are 
not tyrosine and at least one is acidic; incidentally, the 
same is also true for KSR-1 in every species studied. While 
this makes it less likely that tyrosine phosphorylation is 
involved in RAF activation in flies or worms, there is also 
precedent for the involvement of serinelthreonine kinases, 
both unknown and of the protein kinase C family, in the 
activation of mammalian RAF (Dent et al., 199513; Siizeri 
et al., 1992). As well as being activated by protein kinase C 
phosphorylation in vitro, mammalian RAF is also activated 
strongly by phorbol ester treatment of cells. While this has 
been previously assumed to be due to RAF phosphoryla- 
tion by protein kinase C, it is possible that another phorbol 
ester-binding kinase could be involved. No evidence has 
ever been found for the zinc finger of RAF binding to phor- 
bol esters, but clearly it will be necessary to test whether 
phorbol esters (or their physiological counterparts, the di- 
glycerides) might bind to the zinc finger of KSR-1 and 
cause activation of its kinasedomain. If such an interaction 
were to occur, KSR-1 would be activated in response to 
activation of phospholipase Cy by receptor tyrosine ki- 
nases. Activated KSR-1 would synergize with RAS, also 
activated by the receptor tyrosine kinases operating 
through GRB2 and SOS, to give maximal stimulation of 
RAF and hence the downstream MAP kinase pathway. 
The discovery of KSR-1 has provided new challenges 
and taught us some important lessons. Perhaps most im- 
portantly, it has reiterated the fact that the RAS pathway 
is not a simple linear sequence of information transfer, 
even when analyzed by genetics rather than biochemistry, 
but may feature diverging, converging, or parallel 
branches. Furthermore, it revealsonce again the immense 
power of developmental genetics in flies and worms in 
identifying new components of signaling pathways, but 
also exposes the limitations of genetic analysis that is un- 
able to determine the exact map of protein-protein interac- 
tions in a branched pathway without supporting biochemi- 
cal data. Whatever the exact function of KSR-1, it seems 
clear that it has the potential to fill in some of the missing 
pieces in the fascinating jigsaw of RAS function. 
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